Early metabolic response assessment to neoadjuvant endocrine treatment in ER+, HER2-breast cancer: comparison to the morphological and pathological response

被引：0
|
作者：
Boughdad, Sarah [1 ]
Champion, Laurence [1 ]
Becette, Veronique [2 ]
Cherel, Pascal [2 ]
Mouret-Fourme, Emmanuelle [2 ]
Edeline, Veronique [1 ]
Lemonnier, Jerome [3 ]
Lerebours, Florence [2 ]
Alberini, Jean-Louis [1 ]
机构：
[1] Ctr Rene Huguenin, Inst Curie, Nucl Med, St Cloud, France
[2] Ctr Rene Huguenin, Inst Curie, St Cloud, France
[3] Unicancer, Paris, France
来源：
JOURNAL OF NUCLEAR MEDICINE | 2015年 / 56卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1311
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2-breast cancer
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    ONCOTARGET, 2016, 7 (43) : 69111 - 69123
  • [22] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [23] Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer
    Tagliaferri, Barbara
    Quaquarini, Erica
    Palumbo, Raffaella
    Balletti, Emanuela
    Presti, Daniele
    Malovini, Alberto
    Agozzino, Manuela
    Teragni, Cristina Maria
    Terzoni, Andrea
    Bernardo, Antonio
    Villani, Laura
    Sottotetti, Federico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [24] Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
    E. H. Lips
    L. Mulder
    J. J. de Ronde
    I. A. M. Mandjes
    A. Vincent
    M. T. F. D. Vrancken Peeters
    P. M. Nederlof
    J. Wesseling
    S. Rodenhuis
    Breast Cancer Research and Treatment, 2012, 131 : 827 - 836
  • [25] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [26] Real World Data on Neoadjuvant Endocrine Treatment and Ki67 Assessment in ER+/HER2-Breast Cancer. Results from a Single-Institution Prospective Cohort Study
    Marti, Covadonga
    Frias, Laura
    Loayza, Adolfo
    Moreno, Elisa
    Melendez, Marcos
    Sanchez-Mendez, Jose Ignacio
    CANCER RESEARCH, 2023, 83 (05)
  • [27] ASO Visual Abstract: Axillary Response to Neoadjuvant Therapy in Node-Positive ER+/HER2-Breast Cancer Patients-Predictors and Oncologic Outcomes
    Friedman-Eldar, Orli
    Ozmen, Tolga
    El Haddi, Salah James
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susan B.
    Moller, Mecker G.
    Franceschi, Dido
    Layton, Christina
    Avisar, Eli
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (07) : 4102 - 4102
  • [28] Genomic characterization and oncology outcomes of a locally advanced ER+/HER2-breast cancer cohort treated with neoadjuvant chemotherapy
    Abreu, Maira
    Furlan, Larissa
    Ma, Yutong
    Chen, Hanlin
    Ferreira, Carla
    Fares, Aline
    Constantino, Eduardo
    Nora, Gustavo R.
    Lucio, Gabriela
    Colombo, Tatiana
    Liu, Rui
    Wu, Xue
    Ou, Qiuxiang
    Araujo, Daniel V.
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer
    Mazumder, Aloran
    Oropeza, Elena
    Punturi, Nindo
    Haricharan, Svasti
    CANCER RESEARCH, 2023, 84 (06)
  • [30] Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2-breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial
    Goetz, Matthew P.
    Suman, Vera J.
    Fraser, Heather
    Mina, Lida
    Advani, Pooja
    Leon-Ferre, Roberto
    Giridhar, Karthik
    Batalini, Felipe
    Hunt, Katie N.
    Jayaraman, Swaathi
    Jakub, James
    Cronin, Patricia
    Piltin, Mara
    Degnim, Amy
    Ingle, James N.
    Boughey, Judy C.
    Buhrow, Sarah
    Reid, Joel
    Schellenberg, Matthew
    Hawse, John
    Quay, Steven
    CANCER RESEARCH, 2024, 84 (07)
12345